Remove Genetics Remove Packaging Remove RNA
article thumbnail

Merck and Orna partner for RNA technology-based vaccines and therapies

Pharmaceutical Technology

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

RNA 147
article thumbnail

How a virus packages its genetic material

Scienmag

— Each simple RNA virus has a genome, its “native RNA.” RIVERSIDE, Calif. This genome dictates how the virus replicates in cells to eventually cause disease. The genome also has the code for making a capsid, the protein shell of a virus that encapsulates the genome and protects it like a nanocontainer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How did pharma develop a vaccine so quickly?

World of DTC Marketing

Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. These vaccines were developed using different “platform technologies” that involve slotting genetic material from the virus into a tried and tested delivery package.

article thumbnail

Next Generation RNA Therapeutics and Vaccines – A Marvel of The Lifesciences Industry

Roots Analysis

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40
article thumbnail

2021: the year mRNA therapeutics came of age

pharmaphorum

It, too, announced plans to invest $500 million in a new facility in Africa for the production, fill/finish and packaging of mRNA vaccines. Dormitzer comes from Pfizer, where he was chief scientific officer for RNA and viral vaccines for more than six years. The UK firm also recently hired Phil Dormitzer as head of vaccines R&D.

RNA 105
article thumbnail

Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug

pharmaphorum

Intellia and Regeneron’s in vivo approach involves administration of a gene-editing drug – in the form of a CRISPR mRNA and guide RNA packaged in a lipid nanoparticle – directly into the body. . — Eric Topol (@EricTopol) June 26, 2021.

In-Vivo 105
article thumbnail

Protein can release trapped histones in the cell

Scienmag

In the cell nucleus histones play a crucial role packaging DNA into chromatin. Histones are however very sticky to both DNA and RNA, so to ensure they are transported to the cell nucleus after synthesis and bind to the right portion of DNA to organize the chromatin, they are guarded by complexes of histone chaperones. […].

Protein 40